DirectWomen is proud to present its 2025 Ruth Bader Ginsburg Corporate Board Award to Organon & Co.

Organon CEO Kevin Ali will accept the award on behalf of the corporation.

As of 2025, seven of Organon & Co.’s ten non-executive directors are women, including a woman lawyer-director.

About Organon

Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical partners and innovators looking to commercialize their products by leveraging its scale and agile presence in fast growing international markets.

Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.